AMEX:CRMD

Stock Analysis Report

Executive Summary

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has CorMedix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

19.4%

CRMD

2.4%

US Pharmaceuticals

2.3%

US Market


1 Year Return

1.1%

CRMD

-7.7%

US Pharmaceuticals

5.6%

US Market

Return vs Industry: CRMD exceeded the US Pharmaceuticals industry which returned -7.7% over the past year.

Return vs Market: CRMD underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

CRMDIndustryMarket
7 Day19.4%2.4%2.3%
30 Day-27.2%1.1%-1.0%
90 Day-31.3%-1.5%-0.7%
1 Year1.1%1.1%-5.4%-7.7%7.9%5.6%
3 Year-44.2%-44.2%18.8%10.5%45.6%36.3%
5 Year-31.3%-31.3%26.4%13.1%65.8%47.6%

Price Volatility Vs. Market

How volatile is CorMedix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CorMedix undervalued compared to its fair value and its price relative to the market?

8.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate CRMD's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CRMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CRMD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: CRMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CRMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRMD is overvalued based on its PB Ratio (9x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is CorMedix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-92.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRMD's revenue (195.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CRMD's revenue (195.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CRMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CorMedix performed over the past 5 years?

-12.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CRMD is unprofitable, and losses have increased over the past 5 years at a rate of -12.2% per year.

Accelerating Growth: Unable to compare CRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: CRMD has a negative Return on Equity (-84.68%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CRMD is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CRMD is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is CorMedix's financial position?


Financial Position Analysis

Short Term Liabilities: CRMD's short term assets ($27.4M) exceeds its short term liabilities ($4.3M)

Long Term Liabilities: CRMD's short term assets (27.4M) exceeds its long term liabilities (6.7M)


Debt to Equity History and Analysis

Debt Level: CRMD's debt to equity ratio (40.9%) is considered high

Reducing Debt: Insufficient data to determine if CRMD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CRMD has a low level of unsold assets or inventory.

Debt Coverage by Assets: CRMD's debt is covered by short term assets (assets are 4.070640x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CRMD has sufficient cash runway for 1.177807 years if free cash flow continues to reduce at historical rates of -4.5% each year.


Next Steps

Dividend

What is CorMedix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CRMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CRMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CorMedix's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Khoso Baluch (61yo)

3yrs

Tenure

US$586,841

Compensation

Mr. Khoso Baluch has been the Chief Executive Officer of CorMedix, Inc. since October 3, 2016. Mr. Baluch served as Senior Vice President and President Europe, Middle East & Africa EMEA at UCB, SA or UCB,  ...


CEO Compensation Analysis

Compensation vs. Market: Khoso's total compensation ($USD586.84K) is about average for companies of similar size in the US market ($USD1.18M).

Compensation vs Earnings: Khoso's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.1yrs

Average Tenure

62yo

Average Age

Experienced Management: CRMD's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

2.3yrs

Average Tenure

62yo

Average Age

Experienced Board: CRMD's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: CRMD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$33,75001 Oct 19
Steven Lefkowitz
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$6.75
BuyUS$34,05001 Oct 19
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares5,000
Max PriceUS$6.81
BuyUS$6,87901 Oct 19
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max PriceUS$6.88
BuyUS$8,18019 Aug 19
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max PriceUS$8.18
BuyUS$48,36016 Aug 19
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares6,000
Max PriceUS$8.06
BuyUS$50,34416 Aug 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,147
Max PriceUS$8.19
BuyUS$75,11117 May 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares11,144
Max PriceUS$6.74
BuyUS$93501 Apr 19
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares100
Max PriceUS$9.35
BuyUS$18,87527 Mar 19
Khoso Baluch
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares2,500
Max PriceUS$7.55
BuyUS$38,65027 Mar 19
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares5,000
Max PriceUS$7.73
BuyUS$25,35025 Mar 19
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares3,000
Max PriceUS$8.45
BuyUS$33,00022 Mar 19
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares4,000
Max PriceUS$8.25
BuyUS$69,97220 Mar 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,400
Max PriceUS$8.33
BuyUS$23,50021 Dec 18
Wade Capital Corporation, Money Purchase Plan
EntityCompany
Shares4,000
Max PriceUS$5.88
BuyUS$124,41021 Dec 18
Mehmood Khan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares20,000
Max PriceUS$6.22
BuyUS$73,30017 Dec 18
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares10,000
Max PriceUS$7.33
BuyUS$363,15030 Nov 18
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares50,000
Max PriceUS$7.26
BuyUS$30,49527 Nov 18
Khoso Baluch
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares5,000
Max PriceUS$6.40
BuyUS$29,21327 Nov 18
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceUS$5.84
BuyUS$64,79527 Nov 18
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares10,000
Max PriceUS$6.48

Ownership Breakdown


Management Team

  • Jack Armstrong (75yo)

    Head of Human Resources & Executive VP of Technical Operations

    • Tenure: 2.6yrs
    • Compensation: US$369.27k
  • Bob Cook (63yo)

    Chief Financial Officer

    • Tenure: 2.7yrs
    • Compensation: US$434.18k
  • Paul Chew

    Consultant Advisor Chief Medical Officer

    • Tenure: 1.4yrs
  • Liz Masson (40yo)

    Executive VP & Head of Clinical Operations

    • Tenure: 1.6yrs
    • Compensation: US$364.48k
  • Khoso Baluch (61yo)

    CEO & Director

    • Tenure: 3yrs
    • Compensation: US$586.84k
  • Phoebe Mounts

    Executive VP & General Counsel

    • Tenure: 0.4yrs

Board Members

  • Myron Kaplan (73yo)

    Independent Chairman of the Board

    • Tenure: 2.2yrs
    • Compensation: US$70.88k
  • Janet Dillione (60yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$54.42k
  • Steve Lefkowitz (63yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$67.46k
  • C. Webb

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Mehmood Khan (60yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$53.57k
  • Bruce Polsky (65yo)

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Michael Allon

    Chairman of Scientific Advisor Board

    • Tenure: 0yrs
  • Paul Flyer

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Bruce Reidenberg

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Khoso Baluch (61yo)

    CEO & Director

    • Tenure: 3yrs
    • Compensation: US$586.84k

Company Information

CorMedix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CorMedix, Inc.
  • Ticker: CRMD
  • Exchange: AMEX
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$155.668m
  • Shares outstanding: 25.03m
  • Website: https://www.cormedix.com

Number of Employees


Location

  • CorMedix, Inc.
  • 400 Connell Drive
  • Suite 5000
  • Berkeley Heights
  • New Jersey
  • 7922
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRMDAMEX (NYSE MKT LLC)YesClass A Common StockUSUSDMay 2010
19KADB (Deutsche Boerse AG)YesClass A Common StockDEEURMay 2010

Biography

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:16
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.